S&P Futures
5,886.00 -10.25 (-0.17%) Dow Futures
43,122.00 -55.00 (-0.13%) Nasdaq Futures
20,462.25 -57.25 (-0.28%) Russell 2000 Futures
2,249.20 -6.30 (-0.28%) Crude Oil
70.27 -0.29 (-0.41%) Gold
2,742.90 +4.00 (+0.15%)
BioNTech SE (22UA.BE)
- Benzinga
FDA Presses Clinical Hold Button For BioNTech's Partner Late-Stage Trial Of Investigational Lung Cancer Treatment
BioNTech SE (NASDAQ:BNTX) has been notified by its partner, OncoC4 Inc., that the FDA has imposed a partial clinical hold on its Phase 3 PRESERVE-003 trial. The open-label, randomized study evaluates BNT316/ONC-392 (gotistobart) as a monotherapy in patients with metastatic non-small cell lung cancer (NSCLC) who have previously progressed after PD-(L)1-inhibitor treatment. Also Read: Google DeepMind, BioNtech Unveil AI Lab Assistants To Revolutionize Scientific Research. Varying outcomes between
- Pharmaceutical Technology
FDA clamps partial hold on Phase III trial of BioNTech & OncoC4’s NSCLC therapy
A partial clinical hold was placed on the registrational trial after results showed variance between squamous and non-squamous NSCLC patient responses.
- GlobeNewswire
BioNTech to Report Third Quarter 2024 Financial Results and Corporate Update on November 4, 2024
MAINZ, Germany, October 21, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2024 on Monday, November 4, 2024. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. ET (2:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update. To access the live conference call via telephone, please register via
